Effect of difference censored rates between groups in clinical trails

Abstract

Abstract:

AIM: To explore the influence on the results of survival analysis when the censored rates are different between the groups. METHODS: Monte-Carlo method was used to simulate a two-group survival data in clinical trials and to estimate the type I error and the test power of the log-rank test and Cox proportional hazards models in different scenario of different censored rates between groups. RESULTS: If censored rates were equal in both test group and control group, the type I errors were well controlled, the estimates of HR were most accurate, and the power was relatively high. If total censored rates were lower than 30%, the lower censored rate difference between two groups, the higher reliability hypothesis testing results. CONCLUSION: In clinical trials, by ensuring enough sample size, the total censored rate should be controlled within 30%, and the difference of censored rate between the two groups less than 10% was suggested.

Key words: clinical trial, censored ratio, survival analysis, statistical property

CLC Number:

R311

CHEN Mengkai, BAI Jianling, WEI Yongyue, HUANG Lihong, ZHAO Yang, YU Hao. Effect of difference censored rates between groups in clinical trails[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 434-438.

References

［1］Andersen PK, Borgan O, Gill RD. Statistical models based on counting processes［M］. London: Springer, 1993:19-60.
［2］Kleinbaum DG, Klein M. Survival Analysis: A self-learning text［M］.3rd ed. London: Springer, 2012:107-118.
［3］Lee ET, Wang JW. Statistical methods for survival data analysis［M］. New Jersey: John Wiley & Sons, 2015:167-168.
［4］Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in advanced renal-cell carcinoma［J］. N Engl J Med,2015, 373(19):1814-1823.
［5］Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study［J］. Lancet, 2016, 387(10022):968-977.
［6］钱俊. 生存分析中删失数据比例对Cox回归模型影响的研究［D］. 南方医科大学, 2009.
［7］Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration［J］. Cancer Chemother Rep, 1966, 50(3):163-170.
［8］Cox DR. Regression models and life tables［J］.J Royal Statistical Society, 1972, 34(2):187-220.
［9］David WH, Stanley L, Susanne M. Applied survival analysis: regression modeling of time-to-event data［M］. 2nd ed. New Jersey：John Wiley & Sons, 2011:195-222.
［10］Lee ET，Wang JW. Statistical methods for survival data analysis［M］．3rd ed. New Jersey：John Wiley & Sons, 2003:198-220.
［11］Klein JP. Moeschberger ML. Survival analysis: techniques for censored and truncated data［M］. Berlin: Springer Berlin, 2005:21-87.
［12］Bender R, Augustin T, Blettner M. Generating survival times to simulate Cox proportional hazards models ［J］. Stat Med, 2005, 24(11):1713-1723.
［13］陈雯, 陈昂, 夏英华,等. 样本量及删失率对生存分析模型有效性和偏倚性的影响［J］. 中国卫生统计, 2013, 30(1):5-8.

[1]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[2]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[3]	DAI Jiahui, SUN Sijia, XIE Xuefeng. Quality management and indicator system for clinical trials of medical devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
[4]	CHEN Jianfang, LOU Donghua. Design of case report form for oncology clinical trials based on CDASH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
[5]	LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin. Ethical analysis and countermeasures of artificial intelligence application in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
[6]	ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li. Clinical trials of inhalation in pediatric population in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
[7]	LI Shanshan, GU Jingwen, ZHANG Jing, YANG Haijing, LIU Wei, YU Yiqi, ZHANG Wenhong. Design and evaluation of clinical trials of COVID-19 vaccine and monoclonal neutralizing antibody [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 190-197.
[8]	DENG Kunhong, LIU Yaxin, SUN Yuanyuan, CHEN Wenjing, YANG Nan, HU Zhanqing, CHEN Kaifeng, HUANG Jie, XIANG Yuxia, YANG Guoping. Literature analysis of the design and results of the First-In-Human clinical trials of drugs from 2009 to 2020 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 77-85.
[9]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[10]	SHE Zhihua, CHEN Zhou, LIANG Songyue. Construction of informatization system of drug clinical trials ethical review based on cloud architecture [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
[11]	SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan. Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
[12]	OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin. Ethical issues and countermeasures of early phase trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
[13]	HUANG Lihong, WANG Ling, YAN Fangrong, WEI Zhaohui, ZHAO Yang, XIA Jielai, CHEN Feng. New perspectives on the principle of intention to treat in clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 449-453.
[14]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[15]	ZHANG Qian, HU Wei, YU Bin, QIN Huiling, CHEN Mingzhuang, LU Chao. Information construction of drug clinical trials based on literature analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 182-189.